Ratios of serum stem cell factor to serum KIT in GIST patients treated with imatinib
. | Ratio of serum stem cell factor (SCF) to KIT during treatment . | . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Pretreatment . | 1 mo . | 5 mo . | 12 mo . | 15 mo . | 18 mo . | Follow-up . | |||||
| Patients with 12-month ratio available | ||||||||||||
| 1 | 1.0 | 2.2 | 9.4 | 259.0 | 318.0 | 341.0 | PR 31 mo | |||||
| 2 | 1.0 | 4.1 | 25.8 | 33.4 | 39.2 | 20.5 | PR 30 mo | |||||
| 3 | 1.0 | 2.1 | 2.5 | 4.8 | 7.0 | 4.4 | PR 30 mo | |||||
| 4 | 1.0 | 1.8 | 8.0 | 10.9 | NA1 | NA | PR 24 mo | |||||
| 5 | 1.0 | 1.8 | 4.5 | 11.2 | 5.0 | NA | PR 23 mo | |||||
| 6 | 1.0 | 1.3 | 1.7 | 5.3 | 6.2 | NA | PR 23 mo | |||||
| 7 | 1.0 | 1.4 | 3.2 | 7.7 | 8.3 | NA | PR 22 mo | |||||
| 8 | 1.0 | 1.8 | 5.5 | 12.0 | 6.6 | NA | PR → PD 25 mo | |||||
| 9 | 1.0 | 1.3 | 4.0 | 6.2 | 6.5 | 6.6 | PR → PD 17 mo | |||||
| 10 | 1.0 | 3.1 | 6.4 | 4.3 | 5.2 | 5.1 | SD → PD 15 mo | |||||
| 11 | 1.0 | 1.2 | 11.5 | 16.9 | 22.1 | 26.3 | PR → PD 11 mo | |||||
| 12 | 1.0 | 1.3 | 2.3 | 3.1 | NA | NA | PR → PD 6 mo | |||||
| 13 | 1.0 | 2.2 | 4.1 | 6.9 | NA | NA | PD 12 mo | |||||
| Median | 1.0 | 1.8 | 4.5 | 7.7 | 6.8 | 13.6 | — | |||||
| Median for all other patients; N = 53 | 1.0 | 1.8 | 2.7 | NA | NA | NA | — | |||||
. | Ratio of serum stem cell factor (SCF) to KIT during treatment . | . | . | . | . | . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | Pretreatment . | 1 mo . | 5 mo . | 12 mo . | 15 mo . | 18 mo . | Follow-up . | |||||
| Patients with 12-month ratio available | ||||||||||||
| 1 | 1.0 | 2.2 | 9.4 | 259.0 | 318.0 | 341.0 | PR 31 mo | |||||
| 2 | 1.0 | 4.1 | 25.8 | 33.4 | 39.2 | 20.5 | PR 30 mo | |||||
| 3 | 1.0 | 2.1 | 2.5 | 4.8 | 7.0 | 4.4 | PR 30 mo | |||||
| 4 | 1.0 | 1.8 | 8.0 | 10.9 | NA1 | NA | PR 24 mo | |||||
| 5 | 1.0 | 1.8 | 4.5 | 11.2 | 5.0 | NA | PR 23 mo | |||||
| 6 | 1.0 | 1.3 | 1.7 | 5.3 | 6.2 | NA | PR 23 mo | |||||
| 7 | 1.0 | 1.4 | 3.2 | 7.7 | 8.3 | NA | PR 22 mo | |||||
| 8 | 1.0 | 1.8 | 5.5 | 12.0 | 6.6 | NA | PR → PD 25 mo | |||||
| 9 | 1.0 | 1.3 | 4.0 | 6.2 | 6.5 | 6.6 | PR → PD 17 mo | |||||
| 10 | 1.0 | 3.1 | 6.4 | 4.3 | 5.2 | 5.1 | SD → PD 15 mo | |||||
| 11 | 1.0 | 1.2 | 11.5 | 16.9 | 22.1 | 26.3 | PR → PD 11 mo | |||||
| 12 | 1.0 | 1.3 | 2.3 | 3.1 | NA | NA | PR → PD 6 mo | |||||
| 13 | 1.0 | 2.2 | 4.1 | 6.9 | NA | NA | PD 12 mo | |||||
| Median | 1.0 | 1.8 | 4.5 | 7.7 | 6.8 | 13.6 | — | |||||
| Median for all other patients; N = 53 | 1.0 | 1.8 | 2.7 | NA | NA | NA | — | |||||
NA indicates not available; —, not applicable; PR, partial response; PD, progressive disease; and SD, stable disease.